Introduction
Underdiagnosis of celiac disease (CeD) can lead to reduced quality of life (QoL) and possible long-term complications. Why CeD is underdiagnosed is poorly understood and may be related to atypical symptoms or development after childhood.
Aims & Methods
We aimed to identify seropositive individuals in the Dutch longitudinal population biobank Lifelines to characterize the prevalence of CeD and clinical and symptomatic characteristics of undiagnosed likely CeD patients.
Out of 36,320 genotyped individuals (mean age 44.9, sd 16.5) from Lifelines (3 assessments over 15 years), we performed anti-tTG serology testing using the EliA-Celikey-IgA or IgG (Thermo-Fisher) on serum collected at the second assessment point derived from participants with HLA-DQ2/8 (~14000), self-reported CeD (167), irritable bowel syndrome (IBS, n=1452), or inflammatory bowel disease (IBD, n=286), and controls with no reported disease or risk genotype (n=563). Seropositive participants and matched controls were also tested at the first and third assessments. We used extensive measures and questionnaire data to identify differences between seropositives, self-reported CeD, IBD, IBS participants, and healthy controls.
Results
We identified 296 participants with positive serology at the second assessment, 206 with likely (>10x ULN) and 90 with possible CeD (>98th percentile). 134 participants were positive at all assessments, and 37 participants were negative at first assessment, but developed seropositivity. Of 296 seropositives, 249 reported no disease, 20 self-reported CeD, 24 IBS, and 3 IBD. Compared to controls the seropositives have higher thrombocyte and mononuclear cell counts, lower Mean Corpuscular Hemoglobin (MCH) and Mean Corpuscular Volume (MCV), and lower overall cholesterol, HDL and LDL cholesterol levels. Seropositives did not score higher on ROME III discomfort questions than controls, whereas self-reported CeD participants scored similar symptom severity as IBS and IBD participants.
Conclusion
We find many long-term seropositive participants within a population biobank, representing likely undiagnosed CeD patients. Development of seropositivity in adulthood, as identified for 37 individuals, indicates development of CeD later in life. Possible undiagnosed CeD patients self-report few symptoms and show minor clinical differences. Diagnostic follow-up and gluten-free diet are needed to determine if undiagnosed CeD patients in the general population perceive an increased QoL upon treatment.
Disclosure
Iris Jonkers is a consultant of Ipsomics